Related Experiment Video

Updated: May 27, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience

Giuseppe Procopio1, Elena Verzoni, Roberto Iacovelli

  • 1Fondazione IRCCS Istituto Nazionale Tumori, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy. giuseppe.procopio@istitutotumori.mi.it

Expert Review of Anticancer Therapy
|November 5, 2011
PubMed

Insights

Sequential targeted therapies for metastatic renal cell cancer (RCC) did not impact overall survival. Treatment decisions for advanced RCC should consider individual patient factors like performance status and risk classification.

Area of Science:

  • Oncology
  • Nephrology

Background:

  • Metastatic renal cell cancer (RCC) treatment has advanced with targeted therapies, improving patient survival.
  • Optimal sequencing of these therapies remains a subject of debate among experts.

Purpose of the Study:

  • To evaluate the impact of different sequential targeted therapy regimens on overall survival in patients with advanced/metastatic RCC.
  • To identify factors associated with overall survival in this patient population.

Main Methods:

  • Retrospective analysis of 310 patients with advanced/metastatic RCC receiving various targeted agents (sorafenib, sunitinib, bevacizumab, everolimus, temsirolimus, axitinib).
  • Agents were administered alone or sequentially until disease progression or toxicity.
  • Median follow-up was 37 months.

Main Results:

  • Median overall survival (OS) was 22 months, with a 5-year OS of 23.4%.
  • No significant difference in OS was observed between different sequential therapeutic schemes.
  • Worse performance status, absence of nephrectomy, and poor-risk classification (Motzer criteria) were associated with shorter OS.

Conclusions:

  • Targeted therapies are effective in a broad population of advanced RCC patients.
  • Individual patient circumstances, including performance status and risk classification, should guide treatment selection.
  • Sequential treatment strategies did not demonstrate a survival advantage in this study.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...